Business
Cortex Pharmaceuticals Inc., a small biotech firm, and Alkermes Inc. of Cambridge, Mass., said Friday that they have settled a lawsuit over development of a drug to treat cerebral blood vessels, and ended a related licensing agreement.
Oct. 8, 1995
Johnson & Johnson and partner Alkermes Inc. said U.S. regulators rejected their twice-a-month form of the Risperdal schizophrenia drug, sending Alkermes shares down 68%.
July 2, 2002
Genentech Inc. and Alkermes Inc. said Tuesday that they would stop making Nutropin Depot, a long-acting treatment for growth hormone deficiency in children, in a move that Alkermes said would reduce its revenue for the year.
June 2, 2004
Cortex Pharmaceuticals Inc. said Monday that it has been named in a lawsuit by another drug maker alleging breach of agreement.
Nov. 23, 1993
Science & Medicine
Eli Lilly & Co. said Friday that it would terminate development of an inhaled insulin treatment for diabetes, which it was conducting in partnership with Alkermes Inc., after deciding that the product’s potential for commercial success wasn’t strong enough.
March 8, 2008
Amylin Pharmaceuticals Inc., Eli Lilly & Co. and Alkermes Inc. said results from a mid-stage study showed that a long-acting form of their Byetta injection helped patients with Type 2 diabetes improve glucose control.
Aug. 23, 2005
Nature of Business: Develops products for the treatment and diagnosis of age-related degenerative diseases and disorders of the brain.
May 18, 1992
Cortex Pharmaceuticals Inc., a start-up firm that is developing drugs for treating age-related diseases and brain disorders, said Friday that it has hired a new chief executive officer with 32 years’ experience in the drug business.
Feb. 6, 1993
Dow drops 50.31 points after a report shows a decline in existing-home sales. Oil prices continue to worry investors. Bond yields fall.
Aug. 24, 2005
Inhale Therapeutic Systems Inc. shares fell 22% Monday after research raised concerns about the effects of an inhaled insulin product the company is developing with Pfizer Inc. and Aventis.
June 26, 2001